After helping a CRO win Bid Defense, daCRO were asked by the CRO and the company for help in selecting suitable sites for involvement in a proof of concept phase IIa study.
The aim was to use our experience of the Network sites to provide a number of suitable sites for Company approval.
This included the following:
Generation of a list of prospective investigators.
Creation & execution of confidentiality agreements with potential sites.
Creation & assessment of feasibility questionnaire from sites.
Clinical Trial Feasibility
The clinical trial feasibility was a process of evaluating the possibility of conducting this Study in Europe.
In spite of the fact that most Western European countries remain the important centers for conducting clinical trials:
~35% of delay in studies is due to patient recruitment.
Nearly 1/5 of investigators do not enrol any patients.
About 1/3 enrol only 5% of evaluable patients.
In most programs, only 1/3 consistently enrol patients.
These were the challenges we faced.
Results
A Network Advisory Committee was established.
Significant protocol enhancements were achieved from physicians and nurses who would actually run the study.
A total of 30 sites were approached in Europe:
18 in the UK.
8 in Germany.
4 in France.
Methodology
The feasibility assessments consisted of the following:
Clinical aspects.
Site demographics.
Recruitment and retention.
Ethical aspects.
Site infrastructure.
Quality
Results
A list of 8 prospective sites who could deliver these rare patients was generated.
All Sites chosen:
Had experience to run study.
Had a local, certified laboratory facility capable of performing all exams described in the protocol synopsis.
Saw sufficient patients to meet eligibility criteria and therefore would enrol 20 patients within six months.
Had no current or planned research studies with the same target population that would compete.
Outcomes
daCRO were able to help us provide our Client with not only a list of sites who could perform this difficult study, but also ggenerated a list of prospective investigators.
“ Access to this European Cancer Network allowed us to deliver extremely speedy feasibility assessments and governance checks within 4 weeks ”
daCRO respects your privacy and is committed to protecting your Personal Data. This privacy notice discloses the privacy practices for the company daCRO; their website https://dacropharmasolutions.com and their social media pages. This privacy notice applies to information collected by daCRO (and by their website/social media sites). It will notify you of the following:
What Personal Data (and Non-Personal Data) is collected from you (particularly through the website).
Who is collecting Personal Data and who is the responsible person within daCRO.
How it is collected.
How it is used.
With whom it may be shared (and why).
What choices are available to you regarding the use of your data.
The security procedures in place to protect the misuse of your information.
How you can correct any inaccuracies in the information.
Personal/Non-Personal Data Collection, Data Controller and our contact details
daCRO may collect and store your Personal Data i.e. information relating to living individuals which may identify them directly or indirectly. The Personal Data we collect may include items such as: your Name; Email Address; Telephone Number; Postal Address; Location Data; or Online Identifiers. We may also collect and store Non-Personal Data which is data other than Personal Data such as: IP addresses; anonymised Personal Data; System Log Data i.e. website pages visited or events occurring in our operating systems; or some machine-generated data.
The Data Controller is daCRO and we have a Data Protection Officer (DPO) appointed to oversee the response to any queries regarding this Privacy Notice. If you have any queries or wish to exercise your legal rights in regards to your Personal Data, please contact:
daCRO Data Protection Officer
daCRO Research & Education Group
Rm 315 Thomson Building
University of Glasgow
University Avenue
Glasgow
Scotland
UK, G12 8QQ
Tel: +44-141-334-1820
daCRO are the only users with access to your Personal Data and other information which you provide to us. We have access to and/or collect information that is directly observed either via interaction with our website i.e. your IP address, browser information or reference site domain name; our System Logs Data i.e. pages visited or our operating system events; or which you voluntarily give us (providing your consent) via our website contact forms, email or other direct contact method you may use. We will not sell or rent this information to anyone. We will use your information to respond to you, regarding the reason you contacted us.
We process the Personal Data we collect under the following lawful basis: either with your consent – normally to contact you i.e. regarding relevant information or events; to allow us to pursue our legitimate business interests; for contract purposes; or to meet our legal obligations, particularly in regards to pharmacovigilance, regulatory and compliance requirements. We do this for the following purposes:
To provide you with relevant information on daCRO’s business activities, products or services; to respond to your queries or other communication you have submitted through the website; to place cookies and similar technologies.
To analyse the use of our website in order to continuously improve content and measure performance; to optimise and fit the use of our website and our communication to you.
To respond to requests for information from government authorities.
To fulfil requirements of any contract(s) we have.
We will not share your information with any third party outside of our organisation, other than as necessary to fulfil your request/enquiry (consent); to allow us to pursue our legitimate business interests; to comply with legal requirements; or for contractual purposes.
daCRO will retain your Personal Data only for the period necessary to fulfil the purposes outlined in this Notice unless a longer retention period is required or permitted by law.
We may contact you via email in the future to tell you about changes to this privacy policy.
We may also contact you with relevant information or events. If you would like to be contacted regarding relevant information or events i.e. regarding clinical trial updates or conference events please tick the appropriate box.
Choices regarding the use of your Data i.e. your access to and control over information
You may opt out of future contact from daCRO, which relates to potentially relevant information or events, at any time i.e. withdraw your consent in regards to this form of processing of your Data. You may also do the following at any time by contacting us via the email address, postal address given on our website:
Ask to see what data we have about you, if any.
Ask to change/correct data we have about you.
Ask us to delete data we have about you. (Please note that if processing of your data would interfere with our legitimate business interests, legal or contract obligations we may not be able to delete your data. If the data is solely processed to meet your consent needs we may be able to delete data at your request).
Express concerns you have about our use of your data.
You also have the right to lodge a complaint with a supervisory authority.
Security
We take precautions to protect your information. When you submit sensitive information via the website, your information is protected. Wherever we collect sensitive information via our website, that information is encrypted and transmitted to us in a secure way. You can verify this by looking for a lock icon in the address bar and looking for "https" at the beginning of the website address on the Web page.
While we use encryption to protect sensitive information transmitted online via our website, we also protect your other electronic and offline information. Only employees who need the information to perform a specific job (for example, billing or customer service) are granted access to Personal Data. Employees and sub-contractors undergo Data Protection training on commencing employment with daCRO and this training is refreshed annually. The computers/servers for electronic records and filing cabinets for hard copies, in which we store Personal Data, are kept in a secure environment.
If you feel that we are not abiding by this privacy notice, you should contact us immediately via email at carla@dacropharmasolutions.com.
Privacy Notice Document
Updated May 2018 by C.L. Bradley
Reviewed and Approved by F.P.G. Bradley & C.G. Bradley